In order to explore the mechanism(s) underlying the pro-tumorigenic capacity of heparanase, we established an inducible Tet-on system. Heparanase expression was markedly increased following addition of doxycycline (Dox) to the culture medium of CAG human myeloma cells infected with the inducible heparanase gene construct, resulting in increased colony number and size in soft agar. Moreover, tumor xenografts produced by CAG-heparanase cells were markedly increased in mice supplemented with Dox in their drinking water compared with control mice maintained without Dox. Consistently, we found that heparanase induction is associated with decreased levels of CXCL10, suggesting that this chemokine exerts tumor-suppressor properties in myeloma. Indeed, recombinant CXCL10 attenuated the proliferation of CAG, U266 and RPMI-8266 myeloma cells. Similarly, CXCL10 attenuated the proliferation of human umbilical vein endothelial cells, implying that CXCL10 exhibits anti-angiogenic capacity. Strikingly, development of tumor xenografts produced by CAG-heparanase cells overexpressing CXCL10 was markedly reduced compared with control cells. Moreover, tumor growth was significantly attenuated in mice inoculated with human or mouse myeloma cells and treated with CXCL10-Ig fusion protein, indicating that CXCL10 functions as a potent anti-myeloma cytokine.
INTRODUCTION
Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. These macromolecules are most abounded in the subepithelial and subendothelial basement membranes and their cleavage by heparanase leads to disassembly of the extracellular matrix that becomes more susceptible to invasion and dissemination of metastatic tumor cells. Heparanase expression is increased in many types of tumors and this elevation is often associated with more aggressive disease and poor prognosis because of advanced local and distant metastases. [1] [2] [3] [4] [5] In addition, heparanase upregulation in primary human tumors correlates in some cases with tumors larger in size and with enhanced micro vessel density. 3, 5 Similarly, cells engineered to overexpress heparanase are endowed with more rapid expansion of tumor xenografts, 1,2,6-8 while heparanase inhibitors attenuate tumor growth in pre-clinical settings. [9] [10] [11] [12] The molecular mechanism exerted by heparanase to promote tumor development is incompletely understood and likely combines enzymatic activity-dependent and -independent aspects. Heparanase activity can release heparan sulfate-bound growth factors stored in the extracellular matrix as reservoir and thereby promote angiogenesis, 13, 14 while inactive heparanase facilitates the survival and proliferation of tumor cells by activation of signaling molecules such as Akt, epidermal growth factor receptor, Src and signal transducer and activator of transcription. 3, [15] [16] [17] [18] [19] Moreover, heparanase induces the transcription of pro-angiogenic (that is, vascular endothelial growth factor (VEGF)-A, VEGF-C and COX-2), pro-thrombotic (that is, TF), mitogenic (HGF) and osteolyic (RANKL) genes, [20] [21] [22] [23] [24] thus significantly expanding the functional repertoire and mode of action of heparanase. In order to further explore the tumorigenic capacity of heparanase, we established an inducible Tet-on system. Heparanase expression and activity were markedly increased following addition of doxycycline (Dox) to the culture medium of CAG myeloma cells infected with the inducible heparanase gene construct, resulting in increased colony number and size in soft agar. Moreover, tumor xenografts produced by CAG-heparanase cells were noticeably increased in mice supplemented with Dox in their drinking water compared with control mice maintained without Dox. Consistently, we found that heparanase induction by Dox is associated with decreased levels of CXCL10, suggesting that this chemokine exerts tumor-suppressor properties. We provide compelling evidence that CXCL10 exerts anticancer properties in myeloma, attenuating cell proliferation, colony formation and tumor growth.
MATERIALS AND METHODS

Cells and cell culture
CAG myeloma cells were kindly provided by Dr Ben-Zion Katz (Tel Aviv Sourasky Medical Center, Tel Aviv, Israel). 25 U266, RPMI-8226 human and MPC-11 mouse myeloma cells were kindly provided by Dr Ralph Sanderson (University of Alabama at Birmingham, Birmingham, AL, USA). 26 Cells were grown in RPMI-1640 medium (Biological Industries, Beit Haemek, Israel) supplemented with 10% fetal bovine serum and antibiotics. Human umbilical vein endothelial cells were isolated and cultured essentially as described. 27 Isolation, culturing and fluorescence-activated cell sorting analysis of CD138-positive primary myeloma cells from patients with plasma cell leukemia was carried out essentially as described.
(Carlsbad, CA, USA), anti-BrdU monoclonal antibody was from Roche (Indianapolis, IN, USA) and anti-actin monoclonal antibody was from Sigma (St Louis, MO, USA). Recombinant CXCL10, anti-CXCR3 monoclonal antibody and Quantikine enzyme-linked immunosorbent assay for human CXCL-10 were purchased from R&D Systems (Minneapolis, MN, USA) and anti-CXCL10 antibody was from PeproTech (Rocky Hill, NJ, USA). Rabbit polyclonal antibody #1453 was prepared against purified 65 kDa heparanase. 27 Anti-mouse platelet endothelial cell adhesion molecule-1 (CD31) polyclonal antibody was kindly provided by Dr Joseph A Madri (Yale University, New Haven, CT, USA). 29 Horseradish peroxidase-conjugated goat anti-rabbit/mouse antibodies were purchased from Jackson ImmunoResearch (West Grove, PA, USA). Human CXCL10 complementary DNA was purchased from OriGene (Rockville, MD, USA) and subcloned into NSPI-CMV-MCS-myc-HIS viral plasmid. 15 Anti-heparanase and anti-CXCL10 short hairpin RNAs (GIPZ lentiviral short hairpin RNA) were purchased from Thermo Scientific (Waltham, MA, USA).
Construction and expression of CXCL10-Ig
Mouse IgG1 Fc (Hinge CH2-CH3) constant region was cloned from RNA extracted from mouse splenocytes that were cultured for 96 h in the presence of lipopolysaccharide and mouse IL-4. The complementary DNA was ligated into the mammalian expression/secretion vector pSecTag2/ Hygro B (Invitrogen), essentially as described. 30 A different set of primers, 5
0 -ATGAACCCAAGTGCTGCCGTCATTTT-3 0 (sense) and 5 0 -AGGAGCCCTTTTA GACCTTTTTTG-3 0 , was used to amplify complementary DNA-encoding mouse CXCL10. The original k chain leader sequence of pSecTag2/Hygro B vector was replaced by a mCXCL10 leader and coding sequences, resulting in CXCL10-Ig fusion protein. The fusion protein was purified from medium conditioned by Chinese hamster ovary dhfr À / À (DG44) cells (kindly provided by Dr L Chasin, Columbia University, New York, NY, USA) overexpressing CXCL10-Ig fusion protein by a High-Trap protein A affinity column (GE Healthcare, Little Chalfont, UK), as described. 30 The biological activity of CXCL10-Ig fusion protein was evaluated by standard T-cell migration assay. 29 Cell lysates, immunoblotting and heparanase activity assay Cell extracts were prepared using a lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, supplemented with a cocktail of protease inhibitors (Roche). Protein concentration was determined (Bradford reagent, Bio-Rad, Hercules, CA, USA) and 30 mg protein was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions using 12% gels. After electrophoresis, proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad). The membrane was probed with the appropriate antibody followed by horseradish peroxidase-conjugated secondary antibody and a chemiluminescent substrate (Pierce, Rockford, IL, USA), as described. 15 Preparation of dishes coated with extracellular matrix and determination of heparanase enzymatic activity was carried out essentially as described. 15, 16, 31 Tet-on system
The Tet-on expression system (ViraPower HiPerform T-rex Gateway Vector Kit) was established according to the manufacturer's (Invitrogen) instructions utilizing the following primers: heparanase forward-5
0 . Briefly, CAG cells were infected with pLenti3.3/TR virus, which encodes the tetracycline repressor gene. High expressing clones were selected and infected with pLenti6.3/TO/V5-DEST viruses expressing heparanase, 8C 16 or T5 15 variants. Cells were selected with Blasticidin (10 mg/ml; Invitrogen), and expanded. Gene expression was induced by adding Dox (Sigma) to the cell culture medium (1 mg/ml), or to the mice drinking water (2 mg/ml). Drinking water was also supplemented with 5% Sucrose (Sigma).
Real-time PCR
Real-time PCR analyses were performed using ABI PRISM 7000 Sequence Detection System using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The following primers were used: Actin F:
Colony formation in soft agar Dulbecco's modified Eagle's medium (DMEM) (3 ml) containing 0.5% low-melt agarose (Bio-Rad) and 10% fetal calf serum (FCS) was poured into 60-mm Petri dishes. The layer was covered with cell suspension (2 Â 10 3 cells) in 1.5 ml DMEM containing 0.3% low-melt agarose and 10% FCS, followed by addition of 2 ml DMEM containing 10% FCS. Medium was exchanged every 3 days. Colonies were visualized and counted under a microscope 2-5 weeks after seeding, as described previously. 15 
MTT assay
The number of viable cells was evaluated by thiazolyl blue tetrazolium bromide (MTT; Sigma) that measures the activity of cellular enzymes that reduce the tetrazolium dye, MTT, to its insoluble formazan, yielding a purple color. Cells (5 Â 10 3 per well) were grown in 96-well plates for the time indicated. MTT (20 ml of 5 mg/ml) was then added to each well for 2-3 h, followed by centrifugation. The cell pellet was re-suspended in 150 ml of isopropanol and absorbance was measured at 570 nm using an enzyme-linked immunosorbent assay plate reader.
Tumorigenicity and immunohistochemistry
Cells of control-infected, heparanase-infected, heparanase C-terminal domain (8C)-infected and T5-infected CAG myeloma cultures were detached with trypsin/ethylenediaminetetraacetic acid (EDTA), washed with phosphatebuffered saline and brought to a concentration of 1 Â 10 7 cells/ml. Cell suspension (1 Â 10 6 /0.1 ml) was inoculated subcutaneously at the right flank of 5-week-old female severe combined immunodeficient mice (n ¼ 6). Drinking water was supplied with sucrose or sucrose and Dox (2 mg/ml) and was replaced twice weekly. Xenograft size was determined by externally measuring tumors in two dimensions using a caliper. At the end of the experiment, mice were administrated with BrdU (10 ml/g; Amersham, GE Healthcare, Buckinghamshire, UK) and were killed 2 h thereafter. Tumor xenografts were then removed, weighed and fixed in formalin. Paraffinembedded 5 mm sections were subjected to immunostaining with anti-CXCL10, anti-BrdU and anti-platelet endothelial cell adhesion molecule (CD31) antibodies using the Envision kit (Dako, Glostrup, Denmark) according to the manufacturer's instructions, as described previously. 15 Similar experiments were performed with CAG myeloma cells overexpressing heparanase and infected with CXCL10 or control vector. Balb/C and severe combined immunodeficient mice were also inoculated with MPC-11 or CAGheparanase myeloma cells, respectively, and treated with purified CXCL10-Ig fusion protein (200 mg per mouse, three times a week).
Tumor-infiltrating lymphocytes were isolated by a dissociation kit according to the manufacturer's (Miltenyi Biotec, Auburn, CA, USA) instructions. Briefly, tumor samples were carefully washed with Hank's solution containing 2% FCS and 1% EDTA to remove peripheral blood and whittled into small pieces. Cell suspension was then obtained by gentle mechanical dissociation (MACS Dissociator, Miltenyi Biotec). Dissociated cell suspensions was kept on ice for 15 min. The upper layer was carefully recovered, passed through a 70-mm cell strainer (BD Labware, Franklin Lakes, NJ, USA), and layered onto Ficoll-Hypaque separation solution (Lymphoprep; Axis-Shield, Oslo, Norway). Cells were then isolated by density gradient centrifugation and subjected to fluorescence-activated cell sorting analysis using anti-CD8 and anti-NK (BioLegend, San Diego, CA, USA) antibodies.
The Animal Care Committee of the Technion (Haifa, Israel) approved all animal experiments.
Illumina human GX arrays
All RNA samples for gene expression analysis had a RNA integrity number value above 7.5 using Experion system (Bio-Rad). Microarray expression profiling was performed in the Genomics Core Facility of the Rappaport Research Institute at the Technion. The RNA was amplified into complementary RNA and biotinylated by in vitro transcription using the Illumina TargetAmp-Nano Labeling Kit according to the manufacturer's (Epicentre, Illumina Inc., San Diego, CA, USA) protocol, using 100 ng of total RNA as input material. Biotinylated complementary RNAs was purified, fragmented and subsequently hybridized to an Illumina Human HT-12 v4 Bead Chip according to the Direct Hybridization assay (Illumina Inc.).
The hybridized chip was stained with streptavidin-Cy3 (Amersham) and scanned with an Illumina bead array reader. The scanned images were imported into GenomeStudio (Illumina Inc.) for extraction and quality control. The biostatistics analysis was performed using JMP-Genomics Version 5.0, Cary, NC, USA, 1989-2007 (SAS). Probes below the background levels were filtered out. The expression measures were then logtransformed base 2, requiring no further normalization since Illumina gene expression results are extremely robust. Differentially expressed genes were identified using one-way analysis of variance for time point. Significant differentially expressed gene was defined as transcript that has at least twofold changes in expression at P-value of 0.05 after false discovery rate correction.
Statistics
Data are presented as mean ± s.e. Statistical significance was analyzed by two-tailed Student's t-test. The value of Po0.05 was considered significant. All experiments were repeated at least three times with similar results.
RESULTS
Establishment of an inducible (Tet-on) system of heparanase variants In order to investigate the significance of heparanase for tumor development, we established an inducible model system. In this system, gene expression is constantly repressed; gene induction is obtained following the addition of tetracycline or its analog, Dox, to the cell culture medium or mice drinking water. CAG myeloma cells were infected with inducible wild-type heparanase, heparanase C-terminal domain (8C) 16 or T5 (a heparanase splice variant) 15, 32 gene constructs and expression levels were examined in cells grown in the absence or presence of Dox by immunoblotting. Expression of heparanase variants was not detected in the absence of Dox (Figure 1a , left upper panel, -) but was markedly enhanced in cell grown in its presence ( Figure 1a , left upper panel, þ ). Similarly, heparanase enzymatic activity was noticeably increased in cells infected with Tet-on heparanase constructs while no heparanase activity was observed following 8C or T5 induction (Supplementary Figure 1A) , as expected. Moreover, heparanase induction was associated with decreased levels of syndecan-1 on the cell membrane ( Figure 1a , right lower panel), likely representing syndecan-1 shedding reported in myeloma cells overexpressing heparanase. 26 In order to examine the reversibility of the system, Dox was added to CAG cells for 24 h and then removed. Cells were grown in the absence of Dox for additional 1, 2, 3 or 4 days and protein expression was revealed by immunoblotting. Although Dox efficiently stimulated the expression of heparanase variants (Figure 1b, 1) , its withdrawal resulted in a marked decrease in protein levels. Densitometry analysis revealed distinct kinetics of protein elimination. Thus, although the decline in 8C and T5 appeared rapid and the proteins became undetectable 2 days after Dox withdrawal (Figure 1b, 3) , heparanase decrease was slower and could be detected even 3 days following the removal of Dox (Figure 1b , Hepa, 4).
In order to reveal the consequences of heparanase variants induction, we first examined anchorage-independent growth capacity of heparanase-infected, 8C-infected and T5-infected CAG cells. Colony formation in soft agar in term of number and size was increased markedly following heparanase, 8C and T5 induction by Dox (Supplementary Figures 1B and C) , in agreement with the previous results. 15 Similarly, the development of tumor xenografts produced by heparanase-induced, 8C-induced and T5-induced ( þ Dox) cells was prominently enhanced compared with xenografts generated in the absence of Dox (-Dox). On termination of the experiment on day 34, noticeable differences in tumor xenograft development were observed ( Figures 2a and b) ; average weights of heparanase xenografts were 552 ± 175 mg in the presence Dox compared with 77±43 mg in its absence, representing sevenfold increase in tumor weight (Figure 2b ). Even greater increase in tumor weight was obtained following 8C (352 ± 123 vs 42 ± 19 mg) and T5 (695 ± 130 vs 12 ± 12 mg) induction, differences that are statistically highly significant (P ¼ 0.01 for heparanase vs control, P ¼ 0.01 for 8C vs control, and P ¼ 0.0002 for T5 vs control; Figure 2b ).
Heparanase induction is associated with CXCL10 downregulation In order to appreciate alteration in gene expression associated with heparanase induction, we applied gene array methodology. Total RNA was extracted from CAG-heparanase clone 13 cells grown in the absence of Dox (0) Figure 1D , fourth panel) shown previously to be affected by heparanase. 15, 17, 29 Analyzing the results at high stringency (P ¼ 0.001) we found that the expression of 21 genes was altered following heparanase induction, 10 genes were upregulated while 11 were downregulated. We next validated (quantitative PCR) the induction (that is, ATF5, SDF2L1) or repression (that is, CXCL10) of selected genes in clone 13 cells and a pool of CAG cells overexpressing heparanase (Figures 3a  and b) . Regulation of ATF5 and SDF2L1 by heparanase was restricted to clone 13 cells selected for the Tet-on system, but is not common in myeloma. In contrast, we consistently observed a two-and fourfold decrease in CXCL10 (IP10) expression by heparanase in both the CAG clone and pool cells (Figures 3a  and b , right panels) that was statistically highly significant (Po0.01). We further substantiated CXCL10 mRNA downregulation in another CAG-heparanase-inducible clone (#1; Figure 4a ). Moreover, immunostaining of CAG clone #13 revealed a marked decrease in CXCL10 staining in response to Dox (Figure 4b , upper panels), as also verified by enzyme-linked immunosorbent assay determination of CXCL10 (94.3±12.2 ng/ml vs 31.1±17 ng/ml, without or with Dox treatment, respectively; Figure 4b , lower panel; P ¼ 0.0005). Similarly, reduced CXCL10 mRNA expression comparable in magnitude was observed in U266 and RPMI-8266 myeloma cells overexpressing heparanase vs control (Vo) cells (Figure 4c) or following exogenous addition of heparanase (Figure 4d) . Moreover, heparanase gene silencing (Supplementary Figure 2A) was associated with increased CXCL10 expression (Figure 4c , sh-Hepa), collectively implying that heparanase downregulates CXCL10 expression in myeloma cells.
CXCL10 attenuate proliferation, colony formation and tumor development by myeloma cells As reduced CXCL10 expression is associated with heparanase induction and tumor development (Figure 2) , we rationalized that CXCL10 may exhibit tumor-suppressor properties in myeloma. In order to examine this possibility, we used MTT assay to assess cell proliferation. Addition of recombinant CXCL10 to CAG (Figure 5a Overexpressing CXCL10 in these cells resulted in significantly fewer and smaller colonies in soft agar compared with control cells infected with an empty vector (Vo; Figure 5c ; Supplementary Figure 2D ), clearly depicting its anti-proliferative capacity. Applying fluorescence-activated cell sorting analyses, we confirmed that our myeloma cells express CXCR3, the high-affinity receptor for CXCL10 (Figure 5d ), which appears functional because the decrease in cell number following CXCL10 treatment was prevented by neutralizing anti-CXCR3 antibody (Figure 5e , upper and middle panels). Notably, reduced viability was also observed in cells collected from a patient with plasma cell leukemia treated with CXCL10, and this effect was prevented by anti-CXCR3 neutralizing antibody (Figure 5e , lower panel), thus supporting a (Figure 5a , lower panel), thus implying that CXCL10 hampers myeloma progression by decreasing the proliferation rate of both the tumor and endothelial cells.
CXCL10 has a very short half-life in vivo and hence its potential use as a drug is limited. To overcome this, we constructed a chimeric protein composed of CXCL10 fused to IgG1 (Fc). 29 The fusion protein was expressed as a disulphide-linked homodimer, similar to IgG1, yielding a molecular mass of B72 kDa when analyzed under non-reducing conditions, consisting of two identical 36 kDa subunits (Supplementary Figure 3B) . Next, we confirmed that the CXCL10-Ig fusion protein maintains its functional property to attract activated T cells, comparable to recombinant CXCL10 (Supplementary Figure 3C) . Treatment of mice inoculated with CAG-heparanase cells with the CXCL10-Ig fusion protein significantly attenuated tumor development (Figure 6d ). On termination of the experiment on day 21, noticeable differences in tumor xenograft development were observed; average weights of control phosphate-buffered saline-treated tumors were 460±44 mg compared with 260±58 mg for CXCL10-Ig-treated tumors, representing an average decrease of 43% in tumor weight (Figure 6d ). Administration of CXCL10-Ig to mice inoculated with MPC-11 mouse myeloma cell, resulted in even more efficient inhibition of tumor growth (Figure 6e ). On termination of the experiment (day 11), tumors developed in phosphate-buffered saline-treated mice had an average weight of 343 ± 40 mg vs 118 ± 61 mg in the CXCL10-Ig-treated mice, representing an impressive 66% average decrease in tumor weight (Figure 6e) . Moreover, half of the CXCL10-Ig-treated mice failed to develop tumors at all (Figure 6e) . Notably, treatment with CXCL10-Ig was associated with a marked increase in the amount of antitumor CD8 þ (12-fold) and NK (6-fold) cells in the tumor lesion (Figure 6f ), reflecting the ability of CXCL10-Ig to chemoattract antitumor immune cells in vivo. This may provide another path by which CXCL10 suppresses myeloma tumor growth, and altogether indicating that CXCL10 and to a higher extent its Ig fusion protein, is a potential new therapeutic modality for myeloma.
DISCUSSION
Compelling evidence has shown that heparanase is upregulated in various primary solid tumors (that is, carcinomas and sarcomas) and hematological malignancies. 3, 5, 33 Mechanisms responsible for heparanase induction are poorly defined and appear to combine epigenetic, systemic and local mediators that operate at the transcriptional and post-transcriptional levels. 3, 34 The consequence of heparanase induction most often associates with disease progression and bad prognosis because of increased tumor metastasis, thus providing strong clinical support for the pro-metastatic function of heparanase and encouraging the development of heparanase inhibitors. 4, 10, 35 Heparanase appears nonetheless more versatile and promotes the development of primary human tumors via activation of signaling molecules (that is, Akt, Src, epidermal growth factor receptor, IR and signal transducer and activator of transcription) [16] [17] [18] 29, 36 and induction of pro-tumorigenic gene transcription (that is, VEGF, hepatocyte growth factor (HGF) and matrix metalloproteinase 9 (MMP9)). 24, 29, 37 The molecular mechanism(s) exerted by heparanase to promote tumor progression is still incompletely understood. Applying an inducible model system, we clearly demonstrate that heparanase induction markedly promotes colony formation and tumor 38, 39 Many of the pro-tumorigenic effects of heparanase in myeloma have been shown to relay upon increased expression and shedding of syndecan-1. 38 This proteoglycan is expressed on most myeloma tumor cells and is a critical determinant of myeloma cell survival and growth. 40 Cell surface syndecan-1 promotes adhesion of myeloma cells; syndecan-1 remains biologically active after it is shed from cells and can modulate the activity of heparin-binding growth factors. 40 Heparanase enhances syndecan-1 shedding by upregulating the expression of MMP9 and urokinase plasminogen activator that are recognized as syndecan sheddases. 37 In addition, heparanase enhances the expression of HGF that can associate with shed syndecan-1 and facilitate paracrine signaling via its high-affinity receptor, c-Met. 24 Unlike the induction of MMP9 and urokinase plasminogen activator, enhanced expression of HGF does not require heparanase enzymatic activity. 24 Marked stimulation of tumor development by the heparanase C-terminal domain (8C) and the heparanase splice variant T5 (Figure 2 ) that lack enzymatic activity but exhibit signaling properties 15, 16 further implies that enzymatically active and inactive heparanase cooperate to drive myeloma progression.
Utilizing gene array methodology, we have found that heparanase induction associates with CXCL10 downregulation. CXCL10 repression by heparanase was demonstrated in three myeloma cell lines (CAG, U266 and RPMI-8266) following overexpression or exogenous addition of heparanase (Figures 4c and d) . Reduced CXCL10 level as a consequence of heparanase induction was also evident at the protein level in CAG cells grown in the presence of Dox (Figure 4b ) and in corresponding tumor xenografts (Supplementary Figure 3D) . Moreover, heparanase gene silencing resulted in elevation of CXCL10 transcription (Figure 4c , sh-Hepa), collectively implying that heparanase levels inversely associate with CXCL10 expression. CXCL10 is therefore a new member in a growing list of genes regulated by heparanase and associated with tumorigenesis (that is, VEGF, VEGF-C, TF, RANKL, HGF and MMP9). A novel set of genes under heparanase regulation has recently been characterized in T cells. 41 In this context, nuclear heparanase was shown to regulate the transcription of a cohort of inducible immune response genes by controlling histone H3 methylation, 41 further expanding the transcriptional potential of heparanase. Whether a similar mechanism is also exerted by heparanase in the framework of tumor progression is yet to be revealed. Noteworthy, heparanase activity is markedly increased in patients with rheumatoid arthritis, and this induction was associated with a 2.5-fold decrease in CXCL10, 42 further strengthening the inverse correlation between heparanase and CXCL10 in the context of autoimmunity.
The mechanism by which heparanase downregulates CXCL10 transcription is not entirely clear but associates with activation of Src (Supplementary Figure 1D) , Erk and STAT3 (Supplementary Figure 4E) and appears not to relay on heparanase enzymatic activity. This is concluded because CXCL10 repression was observed also when heparanase was added together with potent inhibitors of its catalytic activity (heparin and SST0001; Supplementary Figure 4A) , 4 and because reduced CXCL10 expression was noted by heparanase variants (C-terminal domain (8C) and T5 splice variant) (Supplementary Figures 4B and C) that lack catalytic activity. 15, 16 Downregulation of CXCL10 in the course of tumor progression suggests that this protein exerts tumor-suppressor properties in myeloma. Indeed, recombinant CXCL10 attenuated the proliferation of myeloma cells (Figure 5a ), in agreement with the previous results, 43 and even greater inhibition of proliferation was observed in cells overexpressing CXCL10 (Figure 5b ). Overexpression of CXCL10 was also associated with Figure 4D) , suggesting that CXCL10 may promote apoptosis. Importantly, CXCL10 reduced the viability of myeloma cells collected from a patient with plasma cell leukemia (Figure 5f ), further strengthening its clinical relevance. CXCL10 overexpression resulted in significantly fewer and smaller myeloma colonies in soft agar (Figure 5c ), while CXCL10 gene silencing was associated with increased colony formation in soft agar (Figure 5f ). Moreover, CXCL10 gene silencing resulted in tumor xenografts that were 60% bigger than control myeloma 6 ) were inoculated subcutaneously in BALB/c mice and were treated with PBS (n ¼ 7) or CXCL10-Ig fusion protein (n ¼ 6; 200 mg per mouse every other day). At the end of the experiment on day 11, tumors volume (upper panel) and weight (lower panel) were determined. Tumor cell suspension was prepared as described in 'Materials and Methods' section, and cells were subjected to fluorescence-activated cell sorting (FACS) analysis applying antibodies specific for CD8 (f, left panels) and NK cells (f, right panels). tumors (0.29 ± 0.05 and 0.47 ± 0.09 g for shCon and shCXCL10 tumors, respectively), differences that approached significance (P ¼ 0.06; data not shown). Strikingly, infection of CXCL10 to CAG cells that overexpress heparanase and hence are endowed with high tumorigenic capacity 15 resulted in a marked decrease in tumor development (Figure 6a ). Reduced tumor development following CXCL10 overexpression was associated with a twofold decrease in cell proliferation (Figure 6b ) and tumor angiogenesis (Figure 6c) , clearly depicting anticancer properties of CXCL10 in myeloma. Decreased tumor development in mice treated with the CXCL10-Ig fusion protein (Figures 6d-f ) not only supports the notion that CXCL10 exerts anti-myeloma activity, but also provides a more practical means of implementing this chemokine for the treatment of myeloma. CXCL10 ( ¼ interferon-g-inducible protein of 10 kDa; IP-10) is an interferon-inducible chemokine with potent chemotactic activity on activated effector T cells and other leukocytes expressing its high-affinity G protein-coupled receptor CXCR3. 44, 45 Indeed, administration of CXCL10-Ig to mice inoculated with MPC-11 mouse myeloma cells significantly increased the number of NK and T cytotoxic cells in the myeloma microenvironment, resulting in smaller or no tumors (Figures 6e  and f) . In addition to its role in directing the trafficking of activated T lymphocytes and other leukocytes, CXCL10 acts on other cell types. In particular, CXCL10 exhibits anti-proliferative effect on endothelial cells and inhibits wound healing and tumor angiogenesis. [44] [45] [46] [47] Consequently, overexpression of CXCL10 inhibits the progression of tumor xenografts produced by renal, breast, cervical and lung carcinoma; and fibrosarcoma, melanoma and Burkitt lymphoma cells 44, [48] [49] [50] [51] resulting in tumor necrosis. 52 Moreover, administration of CXCL10 prolonged the survival of mice inoculated with lung carcinoma cells because of decreased lung metastasis. 53 In other model systems and contrary to its tumor-suppressor properties, CXCL10 exhibits tumor-promoting function thought to be mediated by enhanced expression of CXCR3.
44 CXCL10 is upregulated in many human cancers, but is downregulated in others. 44 In myeloma patients, CXCL10 appears to be downregulated (https://www.oncomine.org), yet this aspect requires in-depth investigation. Studies aimed at this direction are currently underway.
Taken together, we describe a novel molecular mechanism that underlines the pro-tumorigenic function of heparanase in myeloma and involves downregulation of CXCL10. This chemokine appear to operate in three independent manners to suppress myeloma progression, directly attenuating myeloma cell proliferation; attenuating endothelial cell proliferation and tumor angiogenesis; and chemoattracting antitumor immune cells. Hence, CXCL10 can be considered as a tumor suppressor in this malignancy. Downregulation of such a tumor suppressor provides growth advantage associated with heparanase induction in myeloma. CXCL10, and especially the CXCL10-Ig fusion protein, may thus possibly be considered as a novel therapeutics in myeloma, along with other molecular determinants that have recently been identified, 54, 55 offering new therapeutic modalities for this incurable disease.
